Activation of Notch pathway is linked with epithelial-mesenchymal transition in prostate cancer cells

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67:7-30; PMID:28055103; http://dx.doi.org/10.3322/caac.21387
   PubMed Web of Science ®Google Scholar
• Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, Ward EM. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. Jama 2015; 314:2054-61; PMID:26575061; http://dx.doi.org/10.1001/jama.2015.14905
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66:271-89; PMID:27253694; http://dx.doi.org/10.3322/caac.21349
   PubMed Web of Science ®Google Scholar
• McCrea E, Sissung TM, Price DK, Chau CH, Figg WD. Androgen receptor variation affects prostate cancer progression and drug resistance. Pharmacol Res 2016; 114:152-62; PMID:27725309; http://dx.doi.org/10.1016/j.phrs.2016.10.001
   PubMed Web of Science ®Google Scholar
• Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 2015; 15:701-11; PMID:26563462; http://dx.doi.org/10.1038/nrc4016
   PubMed Web of Science ®Google Scholar
• Chen H, Zhou L, Wu X, Li R, Wen J, Sha J, Wen X. The PI3K/AKT pathway in the pathogenesis of prostate cancer. Front Biosci (Landmark Ed) 2016; 21:1084-91; PMID:27100493; http://dx.doi.org/10.2741/4443
   PubMed Web of Science ®Google Scholar
• Fisher KW, Montironi R, Lopez Beltran A, Moch H, Wang L, Scarpelli M, Williamson SR, Koch MO, Cheng L. Molecular foundations for personalized therapy in prostate cancer. Curr Drug Targets 2015; 16:103-14; PMID:25547910; http://dx.doi.org/10.2174/1389450115666141229154500
   PubMed Web of Science ®Google Scholar
• Wadosky KM, Koochekpour S. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget 2016; 7:64447-70; PMID:27487144; http://dx.doi.org/10.18632/oncotarget.10901
   PubMed Web of Science ®Google Scholar
• Su Q, Xin L. Notch signaling in prostate cancer: Refining a therapeutic opportunity. Histol Histopathol 2016; 31:149-57; PMID:26521657; http://dx.doi.org/10.14670/HH-11-685
   PubMed Web of Science ®Google Scholar
• Flores AN, McDermott N, Meunier A, Marignol L. NUMB inhibition of NOTCH signalling as a therapeutic target in prostate cancer. Nat Rev Urol 2014; 11:499-507; PMID:25134838; http://dx.doi.org/10.1038/nrurol.2014.195
   PubMed Web of Science ®Google Scholar
• Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling–are we there yet? Nat Rev Drug Discov 2014; 13:357-78; PMID:24781550; http://dx.doi.org/10.1038/nrd4252
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: A little bit of everything but not all the time. Nat Rev Cancer 2011; 11:338-51; PMID:21508972; http://dx.doi.org/10.1038/nrc3035
   PubMed Web of Science ®Google Scholar
• Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update. Nat Rev Clin Oncol 2015; 12:445-64; PMID:25850553; http://dx.doi.org/10.1038/nrclinonc.2015.61
   PubMed Web of Science ®Google Scholar
• Guruharsha KG, Kankel MW, Artavanis-Tsakonas S. The Notch signalling system: Recent insights into the complexity of a conserved pathway. Nat Rev Genet 2012; 13:654-66; PMID:22868267; http://dx.doi.org/10.1038/nrg3272
   PubMed Web of Science ®Google Scholar
• Marignol L, Rivera-Figueroa K, Lynch T, Hollywood D. Hypoxia, notch signalling, and prostate cancer. Nat Rev Urol 2013; 10:405-13; PMID:23712204; http://dx.doi.org/10.1038/nrurol.2013.110
   PubMed Web of Science ®Google Scholar
• Deng G, Ma L, Meng Q, Ju X, Jiang K, Jiang P, Yu Z. Notch signaling in the prostate: Critical roles during development and in the hallmarks of prostate cancer biology. J Cancer Res Clin Oncol 2016; 142:531-47; PMID:25736982; http://dx.doi.org/10.1007/s00432-015-1946-x
   PubMed Web of Science ®Google Scholar
• Leong KG, Gao WQ. The Notch pathway in prostate development and cancer. Differentiation 2008; 76:699-716; PMID:18565101; http://dx.doi.org/10.1111/j.1432-0436.2008.00288.x
   PubMed Web of Science ®Google Scholar
• Carvalho FL, Simons BW, Eberhart CG, Berman DM. Notch signaling in prostate cancer: A moving target. Prostate 2014; 74:933-45; PMID:24737393; http://dx.doi.org/10.1002/pros.22811
   PubMed Web of Science ®Google Scholar
• Alcolea MP, Jones PH. Cell competition: Winning out by losing notch. Cell Cycle 2015; 14:9-17; PMID:25551772; http://dx.doi.org/10.4161/15384101.2014.988027
   PubMed Web of Science ®Google Scholar
• Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004; 64:6854-7; PMID:15466172; http://dx.doi.org/10.1158/0008-5472.CAN-04-2500
   PubMed Web of Science ®Google Scholar
• Zhu H, Zhou X, Redfield S, Lewin J, Miele L. Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. Am J Transl Res 2013; 5:368-78; PMID:23634247
   PubMed Web of Science ®Google Scholar
• Ye QF, Zhang YC, Peng XQ, Long Z, Ming YZ, He LY. Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax. Oncol Lett 2012; 3:879-84; PMID:22741011; http://dx.doi.org/10.3892/ol.2012.572
   PubMed Web of Science ®Google Scholar
• Yong T, Sun A, Henry MD, Meyers S, Davis JN. Down regulation of CSL activity inhibits cell proliferation in prostate and breast cancer cells. J Cell Biochem 2011; 112:2340-51; PMID:21520243; http://dx.doi.org/10.1002/jcb.23157
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang L, Fu Y, Fang F, Jiang Y, Dong Y, Zhu W. CSL regulates AKT to mediate androgen independence in prostate cancer progression. Prostate 2016; 76:140-50; PMID:26437743; http://dx.doi.org/10.1002/pros.23104
   PubMed Web of Science ®Google Scholar
• Danza G, Di Serio C, Ambrosio MR, Sturli N, Lonetto G, Rosati F, Rocca BJ, Ventimiglia G, del Vecchio MT, Prudovsky I, et al. Notch3 is activated by chronic hypoxia and contributes to the progression of human prostate cancer. Int J Cancer 2013; 133:2577-86; PMID:23729168; http://dx.doi.org/10.1002/ijc.28293
   PubMed Web of Science ®Google Scholar
• Kwon OJ, Valdez JM, Zhang L, Zhang B, Wei X, Su Q, Ittmann MM, Creighton CJ, Xin L. Increased Notch signalling inhibits anoikis and stimulates proliferation of prostate luminal epithelial cells. Nat Commun 2014; 5:4416; PMID:25048699; http://dx.doi.org/10.1038/ncomms5416
   PubMed Web of Science ®Google Scholar
• Soylu H, Acar N, Ozbey O, Unal B, Koksal IT, Bassorgun I, Ciftcioglu A, Ustunel I. Characterization of Notch signalling pathway members in normal prostate, prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma. Pathol Oncol Res 2016; 22:87-94; PMID:26341090; http://dx.doi.org/10.1007/s12253-015-9983-y
   PubMed Web of Science ®Google Scholar
• Kwon OJ, Zhang L, Wang J, Su Q, Feng Q, Zhang XH, Mani SA, Paulter R, Creighton CJ, Ittmann MM, et al. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. J Clin Invest 2016; 126:2626-41; PMID:27294523; http://dx.doi.org/10.1172/JCI84637
   PubMed Web of Science ®Google Scholar
• Santio NM, Landor SK, Vahtera L, Yla-Pelto J, Paloniemi E, Imanishi SY, Corthals G, Varjosalo M, Manoharan GB, Uri A, et al. Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and prostate cancer cells. Oncotarget 2016; 7:43220-38; PMID:27281612; http://dx.doi.org/10.18632/oncotarget.9215
   PubMed Web of Science ®Google Scholar
• Revandkar A, Perciato ML, Toso A, Alajati A, Chen J, Gerber H, Dimitrov M, Rinaldi A, Delaleu N, Pasquini E, et al. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence. Nat Commun 2016; 7:13719; PMID:27941799; http://dx.doi.org/10.1038/ncomms13719
   PubMed Web of Science ®Google Scholar
• Lefort K, Ostano P, Mello-Grand M, Calpini V, Scatolini M, Farsetti A, Dotto GP, Chiorino G. Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer. Oncotarget 2016; 7:48011-26; PMID:27384993; http://dx.doi.org/10.18632/oncotarget.10333
   PubMed Web of Science ®Google Scholar
• Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009; 69:2400-7; PMID:19276344; http://dx.doi.org/10.1158/0008-5472.CAN-08-4312
   PubMed Web of Science ®Google Scholar
• Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014; 16:488-94; PMID:24875735; http://dx.doi.org/10.1038/ncb2976
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell 2016; 166:21-45; PMID:27368099; http://dx.doi.org/10.1016/j.cell.2016.06.028
   PubMed Web of Science ®Google Scholar
• De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13:97-110; PMID:23344542; http://dx.doi.org/10.1038/nrc3447
   PubMed Web of Science ®Google Scholar
• Chaffer CL, San Juan BP, Lim E, Weinberg RA. EMT, cell plasticity and metastasis. Cancer Metastasis Rev 2016; 35:645-54; PMID:27878502; http://dx.doi.org/10.1007/s10555-016-9648-7
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15:178-96; PMID:24556840; http://dx.doi.org/10.1038/nrm3758
   PubMed Web of Science ®Google Scholar
• Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013; 19:1438-49; PMID:24202396; http://dx.doi.org/10.1038/nm.3336
   PubMed Web of Science ®Google Scholar
• Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, Diez J, Aranda S, Palomo S, McCormick F, Izpisua-Belmonte JC, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev 2004; 18:99-115; PMID:14701881; http://dx.doi.org/10.1101/gad.276304
   PubMed Web of Science ®Google Scholar
• Saad S, Stanners SR, Yong R, Tang O, Pollock CA. Notch mediated epithelial to mesenchymal transformation is associated with increased expression of the Snail transcription factor. Int J Biochem Cell Biol 2010; 42:1115-22; PMID:20348013; http://dx.doi.org/10.1016/j.biocel.2010.03.016
   PubMed Web of Science ®Google Scholar
• Chanrion M, Kuperstein I, Barriere C, El Marjou F, Cohen D, Vignjevic D, Stimmer L, Paul-Gilloteaux P, Bieche I, Tavares Sdos R, et al. Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut. Nat Commun 2014; 5:5005; PMID:25295490; http://dx.doi.org/10.1038/ncomms6005
   PubMed Web of Science ®Google Scholar
• Zhou J, Jain S, Azad AK, Xu X, Yu HC, Xu Z, Godbout R, Fu Y. Notch and TGFbeta form a positive regulatory loop and regulate EMT in epithelial ovarian cancer cells. Cell Signal 2016; 28:838-49; PMID:27075926; http://dx.doi.org/10.1016/j.cellsig.2016.03.016
   PubMed Web of Science ®Google Scholar
• Fender AW, Nutter JM, Fitzgerald TL, Bertrand FE, Sigounas G. Notch-1 promotes stemness and epithelial to mesenchymal transition in colorectal cancer. J Cell Biochem 2015; 116:2517-27; PMID:25914224; http://dx.doi.org/10.1002/jcb.25196
   PubMed Web of Science ®Google Scholar
• Zhao ZL, Ma SR, Wang WM, Huang CF, Yu GT, Wu TF, Bu LL, Wang YF, Zhao YF, Zhang WF, et al. Notch signaling induces epithelial-mesenchymal transition to promote invasion and metastasis in adenoid cystic carcinoma. Am J Transl Res 2015; 7:162-74; PMID:25755838
   PubMed Web of Science ®Google Scholar
• Sethi S, Macoska J, Chen W, Sarkar FH. Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 2010; 3:90-9; PMID:21139809
   PubMed Web of Science ®Google Scholar
• Du B, Shim JS. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules 2016; 21(7); PMID:27455225; http://dx.doi.org/10.3390/molecules21070965
   PubMed Web of Science ®Google Scholar
• Mitra A, Mishra L, Li S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 2015; 6:10697-711; PMID:25986923; http://dx.doi.org/10.18632/oncotarget.4037
   PubMed Web of Science ®Google Scholar
• Ye QF, Zhang YC, Peng XQ, Long Z, Ming YZ, He LY. siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells. Asian Pac J Cancer Prev 2012; 13:2485-9; PMID:22938409; http://dx.doi.org/10.7314/APJCP.2012.13.6.2485
   PubMedGoogle Scholar
• Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012; 22:373-88; PMID:22975379; http://dx.doi.org/10.1016/j.ccr.2012.07.016
   PubMed Web of Science ®Google Scholar
• Cui D, Dai J, Keller JM, Mizokami A, Xia S, Keller ET. Notch pathway inhibition using PF-03084014, a gamma-secretase inhibitor (GSI), enhances the antitumor effect of docetaxel in prostate cancer. Clin Cancer Res 2015; 21:4619-29; PMID:26202948; http://dx.doi.org/10.1158/1078-0432.CCR-15-0242
   PubMed Web of Science ®Google Scholar
• Stoyanova T, Riedinger M, Lin S, Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK, Drake JM, et al. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2016; 113:E6457-E66; PMID:27694579; http://dx.doi.org/10.1073/pnas.1614529113
   PubMed Web of Science ®Google Scholar
• Sun B, Zhang D, Zhao N, Zhao X. Epithelial-to-endothelial transition and cancer stem cells: Two cornerstones of vasculogenic mimicry in malignant tumors. Oncotarget 2016; PMID:27034014; http://dx.doi.org/10.18632/oncotarget.8461
   PubMed Web of Science ®Google Scholar
• Rossi DJ, Jamieson CH, Weissman IL. Stems cells and the pathways to aging and cancer. Cell 2008; 132:681-96; PMID:18295583; http://dx.doi.org/10.1016/j.cell.2008.01.036
   PubMed Web of Science ®Google Scholar
• Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007; 67:4807-15; PMID:17510410; http://dx.doi.org/10.1158/0008-5472.CAN-06-4608
   PubMed Web of Science ®Google Scholar
• Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov 2014; 13:497-512; PMID:24981363; http://dx.doi.org/10.1038/nrd4253
   PubMed Web of Science ®Google Scholar
• Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer 2013; 13:727-38; PMID:24060864; http://dx.doi.org/10.1038/nrc3597
   PubMed Web of Science ®Google Scholar
• Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao WQ. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res 2001; 61:7291-7; PMID:11585768
   PubMed Web of Science ®Google Scholar
• Whelan JT, Kellogg A, Shewchuk BM, Hewan-Lowe K, Bertrand FE. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. J Cell Biochem 2009; 107:992-1001; PMID:19479935; http://dx.doi.org/10.1002/jcb.22199
   PubMed Web of Science ®Google Scholar
• Nowell CS, Radtke F. Notch as a tumour suppressor. Nat Rev Cancer 2017; 17:145-59; PMID:28154375; http://dx.doi.org/10.1038/nrc.2016.145
   PubMed Web of Science ®Google Scholar
• Bray SJ. Notch signalling in context. Nat Rev Mol Cell Biol 2016; 17:722-35; PMID:27507209; http://dx.doi.org/10.1038/nrm.2016.94
   PubMed Web of Science ®Google Scholar
• Wang L, Hou Y, Yin X, Su J, Zhao Z, Ye X, Zhou X, Zhou L, Wang Z. Rottlerin inhibits cell growth and invasion via down-regulation of Cdc20 in glioma cells. Oncotarget 2016; 7:69770-82; PMID:27626499; http://dx.doi.org/10.18632/oncotarget.11974
   PubMed Web of Science ®Google Scholar